<DOC>
	<DOCNO>NCT00084578</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzymes necessary growth stop blood flow tumor . Rosiglitazone may help tumor cell develop normal bladder cell . PURPOSE : This randomized clinical trial study well give celecoxib together rosiglitazone work treat patient undergo cystoscopic surveillance ( screen ) early-stage noninvasive ( carcinoma situ ) carcinoma ( cancer ) bladder radical cystectomy muscle-invasive carcinoma ( cancer spread muscle layer bladder tissue ) bladder .</brief_summary>
	<brief_title>Celecoxib Rosiglitazone Treating Patients Who Are Undergoing Cystoscopic Surveillance Early-Stage Noninvasive Carcinoma Bladder Radical Cystectomy Muscle-Invasive Carcinoma Bladder</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether rosiglitazone celecoxib , administer alone combination , cause change expression effector molecule , peroxisome proliferator-activated receptor-γ ( PPAR-γ ) cyclo-oxygenase-1 ( COX-1 ) , patient early-stage non-invasive carcinoma bladder undergo cystoscopic surveillance patient muscle-invasive carcinoma bladder undergo radical cystectomy . Secondary - Determine whether regimen result change expression downstream effector molecule mediate cellular proliferation apoptosis patient . - Determine relationship tissue level biomarkers drug effect , proliferation , apoptosis systemic biomarkers response treatment , term COX-2 activity level endogenous PPAR-γ ligand , patient treat regimen . - Determine toxicity regimens patient . - Determine frequency recurrence time progression patient undergo cystoscopic surveillance . OUTLINE : This randomize , pilot , cohort study . Patients assign 1 2 cohort accord disease stage ( Ta , Tis , T1 , N0 , M0 vs T2-4 , NX , M0 ) . - Stage 1 : - Cohort 1 : Patients receive oral celecoxib twice daily oral rosiglitazone daily 1 year absence disease progression unacceptable toxicity . - Cohort 2 : Patients receive oral celecoxib twice daily oral rosiglitazone daily 14 day . Patients undergo cystectomy . - Stage 2 : Patients randomize 1 2 treatment arm . - Arm I : - Cohort 1 : Patients receive oral celecoxib twice daily 1 year absence disease progression unacceptable toxicity . - Cohort 2 : Patients receive oral celecoxib twice daily 14 day . Patients undergo cystectomy . - Arm II : - Cohort 1 : Patients receive oral rosiglitazone daily 1 year absence disease progression unacceptable toxicity . - Cohort 2 : Patients receive oral rosiglitazone daily 14 day . Patients undergo cystectomy . Patients cohort 1 ( stage ) undergo cystoscopic surveillance every 3 month . PROJECTED ACCRUAL : A total 120 patient ( 20 per cohort study stage 1 ; 40 per treatment arm [ 20 per cohort arm ] study stage 2 ) accrue study within 12-18 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically clinically confirm bladder cancer Cohort 1 Papillary transitional cell carcinoma urinary bladder Stage Ta T1 ( grade 1 2 ) , N0 , M0 disease Must undergone complete transurethral resection bladder within past 28 day AND/OR Carcinoma situ urinary bladder Stage Tis , N0 , M0 disease Must undergone biopsy within past 28 day No histological pathological evidence invasion underlie muscle ( stage T2 ) Cohort 2 Muscleinvasive papillary transitional cell carcinoma urinary bladder Stage T24 , NX , M0 disease Intending undergo radical cystectomy Must upper tract ( ureter renal pelvic ) evaluation intravenous pyelogram , CT scan , MRI prove normal within past year PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC &gt; 4,000/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) SGOT SGPT &lt; 3 time ULN Renal Creatinine ≤ 2.5 mg/dL Other No malignancy within past 3 year except noninvasive bladder cancer , adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix No history uncontrolled peptic ulcer disease No history unexplained hypoglycemia No known sensitivity celecoxib rosiglitazone No allergy sulfonamides No history asthma , urticaria , allergic reaction take aspirin NSAIDs No underlie uncontrolled medical illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 month since prior intravesical BCG Chemotherapy No prior intravesical systemic chemotherapy Endocrine therapy No concurrent insulin Radiotherapy Not specify Surgery See Disease Characteristics Other At least 2 week since prior use nonsteroidal antiinflammatory drug ( NSAIDs ) ( include COX2 inhibitor ) 3 consecutive day except lowdose ( 81 mg ) aspirin No concurrent betablockers No concurrent NSAIDs No concurrent oral hypoglycemic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>